6533b826fe1ef96bd12853c6

RESEARCH PRODUCT

N-(2-methyl-indol-1H-5-yl)-1-naphthalenesulfonamide : a novel reversible antimitotic agent inhibiting cancer cell motility

José M. LlinaresPriam VillalongaSilvia Fernández De MattosCristina Galiana-rosellóM. Eugenia González-rosendeRafael PeláezRuth Villalonga-planellsEnrique García-españaGuillem RamisClara Aceves-luquero

subject

0301 basic medicineIndolesSulfonamides - Therapeutic use.MotilityApoptosisAntimitotic AgentsMicrotubulesBiochemistryJurkat Cells03 medical and health sciences0302 clinical medicineCell MovementTubulinMicrotubuleCélulas cancerosas - Motilidad.Apoptosis.HumansSulfamidas - Uso terapéutico.MitosisCell ProliferationPharmacologySulfonamidesMolecular StructurebiologyCancer cells - Motility.Cell cycleCell biologyMitosis.030104 developmental biologyTubulinCell cultureApoptosis030220 oncology & carcinogenesisCancer cellMCF-7 Cellsbiology.proteinDrug Screening Assays AntitumorDNA Damage

description

Este es el post-print que se ha publicado de forma definitiva en: https://www.sciencedirect.com/science/article/abs/pii/S0006295216301423 A series of compounds containing the sulfonamide scaffold were synthesized and screened for their in vitro anticancer activity against a representative panel of human cancer cell lines, leading to the identification of N-(2-methyl-1H-indol-5-yl)-1-naphthalenesulfonamide (8e) as a compound showing a remarkable activity across the panel, with IC50 values in the nanomolar-to-low micromolar range. Cell cycle distribution analysis revealed that 8e promoted a severe G2/M arrest, which was followed by cellular senescence as indicated by the detection of senescence-associated b-galactosidase (SA-b-gal) in 8e-treated cells. Prolonged 8e treatment also led to the onset of apoptosis, in correlation with the detection of increased Caspase 3/7 activities. Despite increasing c-H2A.X levels, a well-established readout for DNA double-strand breaks, in vitro DNA binding studies with 8e did not support interaction with DNA. In agreement with this, 8e failed to activate the cellular DNA damage checkpoint. Importantly, tubulin staining showed that 8e promoted a severe disorganization of microtubules and mitotic spindle formation was not detected in 8e-treated cells. Accordingly, 8e inhibited tubulin polymerization in vitro in a dose-dependent manner and was also able to robustly inhibit cancer cell motility. Docking analysis revealed a compatible interaction with the colchicine-binding site of tubulin. Remarkably, these cellular effects were reversible since disruption of treatment resulted in the reorganization of microtubules, cell cycle re-entry and loss of senescent markers. Collectively, our data suggest that this compound may be a promising new anticancer agent capable of both reducing cancer cell growth and motility. This is the peer reviewed version of the following article: Aceves-Luquero, C., Galiana-Roselló, C., Ramis, G., Villalonga-Planells, R., García-España, E., Fernández de Mattos, S. et al. (2016). N-(2-methyl-indol-1H-5-yl)-1-naphthalenesulfonamide : a novel reversible antimitotic agent inhibiting cancer cell motility. Biochemical Pharmacology, vol. 115, pp. 28-42, which has been published in final form at https://doi.org/10.1016/j.bcp.2016.06.016 Este es el post-print del siguiente artículo: Aceves-Luquero, C., Galiana-Roselló, C., Ramis, G., Villalonga-Planells, R., García-España, E., Fernández de Mattos, S. et al. (2016). N-(2-methyl-indol-1H-5-yl)-1-naphthalenesulfonamide : a novel reversible antimitotic agent inhibiting cancer cell motility. Biochemical Pharmacology, vol. 115, pp. 28-42, que se ha publicado de forma definitiva en https://doi.org/10.1016/j.bcp.2016.06.016

10.1016/j.bcp.2016.06.016http://hdl.handle.net/10637/10593